CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...
Phase 2
Stamford, Connecticut, United States and 9 other locations
or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...
Phase 2
Stony Brook, New York, United States and 44 other locations
the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple...
Phase 2
Hartford, Connecticut, United States and 11 other locations
maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast...
Phase 1
Norwalk, Connecticut, United States and 3 other locations
a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast...
Phase 1
Norwalk, Connecticut, United States and 7 other locations
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...
Phase 1, Phase 2
Norwalk, Connecticut, United States and 49 other locations
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-n ...
Phase 2
Stamford, Connecticut, United States and 9 other locations
before the standard surgical procedure, to treat TNBC or HR+ HER2- breast cancers. The study drugs could shrink cancer, bu...
Phase 2
Commack, New York, United States and 6 other locations
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Danbury, Connecticut, United States and 160 other locations
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effec...
Phase 2
Commack, New York, United States and 7 other locations
Clinical trials
Research sites
Resources
Legal